Effects of lecithin: cholesterol acyltransferase genotypes, enzyme levels, and activity on high-density lipoprotein levels. 2011

Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
Department of Medical Biology and Genetics, Marmara University School of Medicine, Istanbul, Turkey; Department of Medical Biology, Acibadem University School of Medicine, Istanbul, Turkey.

BACKGROUND Lecithin:cholesterol acyltransferase (LCAT) is one of the key enzymes controlling cholesterol homeostasis and plays a primary role in high-density lipoprotein cholesterol (HDL-C) maturation. OBJECTIVE The aim of our study was to evaluate the effects of LCAT gene polymorphisms 511C/T (exon4), 4886C/T (rs5923), and 608C/T (rs5922) on LCAT enzyme level, activity, and HDL-C levels. METHODS The study population was selected from consecutive subjects with low (<35 mg/dL) and high HDL-C levels (>65 mg/dL) seen in our lipid clinic. LCAT polymorphisms were analyzed with a restriction fragment length polymorphism assay. LCAT activity and levels were measured by colorimetric enzymatic and enzyme-linked immunoassay methods, respectively. RESULTS The 4886C/T polymorphism was the most commonly observed variant of LCAT gene. T-allele frequencies in subjects with low (n = 50) and high (n = 50) HDL-C were 0.54 and 0.37, respectively (P = .019). TT genotype was more common among low HDL-C group (30% vs 14%, P = .05). The effects of LCAT enzyme appeared to depend on the HDL-C level. In subjects with low HDL-C, LCAT enzyme levels correlated positively with body mass index (P < .001, r = 0.544), HDL-C (P = .006, r = 0.404), triglycerides (P = .001, r = 0.487), total cholesterol (P < .001, r = 0.541), and low-density lipoprotein-cholesterol (P = .001, r = 0.477) levels. LCAT activity correlated positively with fasting glucose levels (P = .008, r = 0.390). CONCLUSIONS LCAT genotype, enzyme level, and activity modulate HDL-C metabolism, particularly among subjects with low HDL-C levels.

UI MeSH Term Description Entries
D007862 Phosphatidylcholine-Sterol O-Acyltransferase An enzyme secreted from the liver into the plasma of many mammalian species. It catalyzes the esterification of the hydroxyl group of lipoprotein cholesterol by the transfer of a fatty acid from the C-2 position of lecithin. In familial lecithin:cholesterol acyltransferase deficiency disease, the absence of the enzyme results in an excess of unesterified cholesterol in plasma. Lecithin Cholesterol Acyltransferase,Cholesterol Ester Lysolecithin Acyltransferase,Lecithin Acyltransferase,Phosophatidylcholine-Sterol Acyltransferase,Acyltransferase, Lecithin,Acyltransferase, Lecithin Cholesterol,Acyltransferase, Phosophatidylcholine-Sterol,Cholesterol Acyltransferase, Lecithin,O-Acyltransferase, Phosphatidylcholine-Sterol,Phosophatidylcholine Sterol Acyltransferase,Phosphatidylcholine Sterol O Acyltransferase
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies

Related Publications

Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
June 2016, Endocrinology and metabolism (Seoul, Korea),
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
May 2013, International journal of sports medicine,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
January 1980, Voprosy meditsinskoi khimii,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
April 1996, Bioscience, biotechnology, and biochemistry,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
June 2001, Journal of lipid research,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
July 2021, Journal of the American Heart Association,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
January 1980, Voprosy meditsinskoi khimii,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
October 2002, Metabolism: clinical and experimental,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
October 1980, The Journal of biological chemistry,
Deniz Agirbasli, and Beyazit Cirakoglu, and Fatih Eren, and Mutlu Sumerkan, and Sukru Aksoy, and Cenk Aral, and Mehmet Agirbasli
August 1972, Biochimica et biophysica acta,
Copied contents to your clipboard!